

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: markspencer

Timestamp: Wed Jul 11 13:17:34 EDT 2007

=====

Validated By CRFValidator v 1.0.2

Application No: 10598975 Version No: 1.0

Input Set:

Output Set:

Started: 2007-07-10 17:53:58.962
Finished: 2007-07-10 17:53:59.084
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 122 ms
Total Warnings: 1
Total Errors: 0
No. of SeqIDs Defined: 11
Actual SeqID Count: 11

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (11)

SEQUENCE LISTING

<110> Cohen, David I.

<120> Tat-based Immunomodulatory Compositions and Method of Using Same

<130> 51311-00008

<140> 10598975

<141> 2007-07-10

<150> 10/598,975

<151> 2006-09-15

<150> PCT/US05/008519

<151> 2005-03-16

<150> 60/533,733

<151> 2004-03-16

<150> 10/456865

<151> 2003-06-06

<150> 09/636057

<151> 2000-08-08

<160> 11

<170> PatentIn version 3.3

<210> 1

<211> 101

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 1

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
1 5 10 15

Gln Pro Lys Thr Ala Cys Thr Thr Cys Tyr Cys Lys Lys Cys Cys Phe
20 25 30

His Cys Gln Val Cys Phe Thr Lys Lys Ala Leu Gly Ile Ser Tyr Gly
35 40 45

Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Pro Glu Asp Ser Gln Thr
50 55 60

His Gln Val Ser Pro Pro Lys Gln Pro Ala Pro Gln Phe Arg Gly Asp
65 70 75 80

Pro Thr Gly Pro Lys Glu Ser Lys Lys Lys Val Glu Arg Glu Thr Glu
85 90 95

Thr His Pro Val Asp
100

<210> 2
<211> 303
<212> DNA
<213> Human immunodeficiency virus type 1

<400> 2
atggagcccg tggaccctcg cctggagccc tggaagcacc cgggcagcca gcccaagacc 60
gctgcacca catgttactg caagaagtgc tgcttccact gccaggtgtg cttaccaag 120
aaggccttgg gcatcagcta cggccgcaag aagcgcgggc agcgccgccc ggcccctgag 180
gacagccaga cccaccaggt gagccctccc aagcagcccg ctccacagtt ccgcggcgac 240
cctaccggtc ccaaggagag caagaagaag gtggagcgcg agaccgagac ccatcccgtc 300
gac 303

<210> 3
<211> 17
<212> PRT
<213> Human immunodeficiency virus type 1
<400> 3

Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro
1 5 10 15

Lys

<210> 4
<211> 21
<212> PRT
<213> Human immunodeficiency virus type 1
<400> 4

Pro Cys Asp Trp Pro Leu Thr Pro Asp Pro Trp Val Tyr Ser Gly Ser
1 5 10 15

Gln Pro Lys Val Pro
20

<210> 5
<211> 27
<212> PRT
<213> Simian immunodeficiency virus

<400> 5

Pro Leu Arg Glu Gln Glu Asn Ser Leu Glu Ser Ser Asn Glu Arg Ser
1 5 10 15

Ser Cys Ile Leu Glu Ala Asp Ala Thr Thr Pro
20 25

<210> 6
<211> 11
<212> PRT
<213> Human immunodeficiency virus type 1

<400> 6

Ser Asn Glu Arg Ser Ser Cys Glu Leu Glu Val
1 5 10

<210> 7
<211> 16
<212> PRT
<213> Human immunodeficiency virus type 1

<400> 7

Cys Thr Thr Cys Tyr Cys Lys Lys Cys Cys Phe His Cys Gln Val Cys
1 5 10 15

<210> 8
<211> 50
<212> DNA
<213> Human immunodeficiency virus type 1

<400> 8

ccagtagatc ctagactaga gccctggaag catccaggaa gtcagcctaa 50

<210> 9
<211> 63
<212> DNA
<213> Mus musculus

<400> 9

ccatgtgact ggcccctgac cccgcacccc tgggtatact ccgggggcca gcccaaagtg 60

ccc 63

<210> 10
<211> 33
<212> DNA
<213> Simian immunodeficiency virus

<400> 10
agcaacgagc ggagttcctg cgagtttagag gtg

33

<210> 11
<211> 98
<212> PRT
<213> Artificial

<220>
<223> Modified immunostimulatory Tat

<400> 11

Met Glu Pro Ser Asn Glu Arg Ser Ser Cys Glu Leu Glu Val Pro Lys
1 5 10 15

Thr Ala Cys Thr Thr Cys Tyr Cys Lys Lys Cys Cys Phe His Cys Gln
20 25 30

Val Cys Phe Thr Lys Lys Ala Leu Gly Ile Ser Tyr Gly Arg Lys Lys
35 40 45

Arg Arg Gln Arg Arg Arg Ala Pro Glu Asp Ser Gln Thr His Gln Val
50 55 60

Ser Pro Pro Lys Gln Pro Ala Pro Gln Phe Arg Gly Asp Pro Thr Gly
65 70 75 80

Pro Lys Glu Ser Lys Lys Lys Val Glu Arg Glu Thr Glu Thr His Pro
85 90 95

Val Asp